Hence, CD47 serves as a target in the treatment of acute mylocytic leukemia (AML) by utilizing antibodies against CD47 to facilitate AML elimination by macrophages, which results in the blockade of inhibitory CD47–SIRPα signaling (21, 22). This evidence concerns the gene CD47 and acute myeloid leukemia.